Abstract: A method for predicting efficacy of treatment of a lung cancer patient using an immune checkpoint inhibitor includes isolating exosomes from a biological sample derived from the lung cancer patient, and determining an expression level of a protein present in the exosomes by a mass spectrometry method, in which the protein is one or more proteins selected from the group of proteins shown in Table 1-1 to Table 1-6.

Abstract: The present invention relates to a method for assaying soluble GPC3 protein in a test sample, comprising using two different antibodies binding to different epitopes present in the N-terminal region of GPC3 protein.

Abstract: A method for separating a vesicle having a lipid bilayer membrane from a biological sample, includes forming a complex of a vesicle and a solid phase carrier by bringing the biological sample containing the vesicle having the lipid bilayer membrane into contact with the solid phase carrier to which a ligand for recognizing a surface antigen present on a surface of the vesicle is bound. The complex is washed. The forming is performed in the presence of a nonionic surfactant which does not comprise an aromatic group to reduce an aggregation of the complex.

Abstract: The present invention relates to a method for assaying soluble GPC3 protein in a test sample, comprising using two different antibodies binding to different epitopes present in the N-terminal region of GPC3 protein.

Abstract: To provide a method for separating a vesicle having a lipid bilayer membrane, which has excellent efficiency of removing impurities and is unsuch asly to cause disruption of the vesicle having a lipid bilayer membrane. A method for separating the vesicle having the lipid bilayer membrane including: a complex forming step for forming a complex of the vesicle and the solid phase carrier by bringing a biological sample including a vesicle having a lipid bilayer membrane into contact with a solid phase carrier to which a ligand for recognizing a surface antigen present on a surface of the vesicle and is bound, a washing step for washing the complex, wherein at least any of the complex forming step and the washing step is performed in the presence of a nonionic surfactant.

Abstract: The present invention provides a therapeutic or prophylactic agent for systemic inflammatory response syndrome (SIRS), which contains a polypeptide comprising an amino acid sequence the same or substantially the same as the amino acid sequence of the N-terminal domain of pentraxin 3 capable of binding to histone to form a polypeptide aggregate, or a pharmacologically acceptable salt thereof. The present invention also provides a reagent for quantification and a quantification method of histone, which utilize the polypeptide or a pharmacologically acceptable salt thereof. Furthermore, the present invention provides a polypeptide aggregate containing the polypeptide or a pharmacologically acceptable salt thereof and histone and a production method thereof.